MAPESolutions is constantly improving to be recognized, throughout Latin America, as the main company in the segment to present innovative solutions aimed at the sustainability of health systems.
Opening Hours
Mon – Fri: 08.00 – 17.00
E-mail: contato@mapesolutions.com
Copyright © Mapes - Powered by Traction
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Healthcare Technology Assessments (HTA)are important tools for the (dis)incorporation of technologies and, for this purpose, they make use of various methods of clinical epidemiology and biostatistics to generate scientific evidence, making it possible to offer managers for decision making based on local evidence. In this sense, the so-called Real-world Data (RWD) or “real-life data” is the raw material for the generation of Real-world Evidence (RWE) “real-world evidence”, which will be of great use to various stakeholders of the Marketplace. In this Article, we’ll talk more about RWD/RWE and how it has been used in Brazil and worldwide.
Why use Real-world Evidence (RWE) in HTA?
As the name implies, Real-world Data (RWD) is generated based on data collected in the real-world and therefore outside the context of traditional clinical studies. Among the possibilities of RWD are electronic medical systems records and administrative records. By using a less controlled environment as a basis, the RWE allows working with broader and more diverse populations, which reflect the day-to-day assistance.
It is not, however, a matter of replacing clinical studies, but of complementing them, answering questions that traditional clinical research alone is not capable of answering. The RWE allows you to check, for example, if a certain drug has the same performance in a less controlled environment (on a daily basis).
Specialists believe that the RWE must become increasingly relevant to develop new practices in the healthcare sector, due to the speed with which information is accessed and with which it is possible to form online communities of patients, with clinical data, allowing accelerated studies. In addition, the cost of using RWE is lower than phase 3 clinical trials or multicenter prospective cohorts.
Among the positive results that this can bring are the improvement in health care and the use of new products in a more comprehensive and optimized way. There are different RWE methodologies and designs, which differ according to available information, research question, and other criteria.
RWE in the world
Real World Evidence (RWE) methodologies are already widespread in the United States, especially for private health-insurance companies and clinical practice guides. In some European countries, such as the UK, France, the Netherlands and the Nordic countries, there is also a policy for the use of databases and records considered acceptable for ATS.
RWE in Brazil and Latin America
Today, in developed countries, RWE is used for some clear purposes, such as:
In Latin America, the adoption of studies based on RWE must pay attention to specific aspects of each region. Among them are:
The adoption of RWE in Brazil and Latin America could mean a new, better-informed phase in the decision-making process regarding health technologies. However, this requires that regulatory agencies and ATS assessments understand the value of an RWE’s information and use it to inform decisions that will benefit Brazilian citizens.
To learn more about ATS and the process of incorporating health technologies, download the e-book MAPES: Cases &Soluções.
Recent Posts
Popular Post
Como a tecnologia pode garantir o conceito
20/10/2021Importance of monitoring the clinical outcome of
15/03/2021The importance of economic evaluation in the
19/01/2021Popular Categories
Archives